医院获得性肺炎患者克雷伯菌、大肠埃希菌中超广谱β-内酰胺酶菌株的发生率和耐药特点分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (28 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the incidence and drug resistance of extended spectrum β-lactamases in Klebsiella and Escherichia coli from patients with hospital acquired pneumonia.Methods A total of 104 patients with hospital acquired pneumonia admitted to the First People′s Hospital of Ji′an City from March 2018 to January 2020 were selected for retrospective analysis.The DL-96Ⅱwas mainly used for drug sensitivity test and strain identification,extended spectrum β-lactamases were detected by Kirby-Bauer method,and their incidence and drug resistance characteristics were analyzed.Results There was no significant difference in the positive rate of extended spectrum β-lactamases between Klebsiella and Escherichia coli(P>0.05).Extended spectrum β-lactamases in Escherichia coli showed drug resistance to Ampicillin,Paediatric Compound Sulfamethoxazole Tablets,Aztreonam,Cefperazone/Sulbactam,Piperacillin/Tazobactam,Ceftazidime,Levofloxacin,Imipenem,Cefoxitin and Amikacin,and promoted over time.Conclusion The incidence of extended spectrum β-lactamases in Klebsiella and Escherichia coli from patients with hospital acquired pneumonia is high,and drug resistance also shows gradually increasing trend in recent years.

Key words： Hospital acquired pneumonia Klebsiella Escherichia coli Extended spectrum &beta -lactamases Incidence Drug resistance

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GONG Wei
	CHEN Ying-hua
	ZHAO Jian-min

Cite this article:

GONG Wei,CHEN Ying-hua,ZHAO Jian-min. Analysis on the incidence and drug resistance of extended spectrum βlactamases in Klebsiella and Escherichia coli from patients with hospital acquired pneumonia[J]. 中国当代医药, 2021, 28(17): 190-192.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I17/190

[1]	段瑶，马序竹，林金兰，等.肺炎克雷伯菌血流感染的临床特征及耐药性分析[J].中国临床药理学杂志，2019，35（15）：1584-1587.
[2]	姚建文，吴文，董亮，等.单中心儿童腹腔感染产超广谱β-内酰胺酶大肠埃希菌的耐药性分析[J].天津医科大学学报，2018，24（4）：325-327.
[3]	刘春红，薛卫强.院内获得性肺炎多重耐药菌感染的流行特征及耐药情况分析[J].国际医药卫生导报，2019，25（4）：585-589.
[4]	欧焕娇，向蓉.我院常见病原菌分布及耐药性分析[J].中国当代医药，2019，26（5）：187-190，254.
[5]	杨汉华，谢淑霞，温丽华，等.新生儿医院获得性大肠埃希菌血流感染临床特征及耐药分析[J].国际流行病学传染病学杂志，2018，45（5）：305-308.
[6]	杨燕文，吴梦莹，张庆.脑卒中合并医院获得性肺炎患者的病原菌分布与耐药性分析[J].检验医学与临床，2019，16（19）：2842-2844.
[7]	张小团，刘卓然，李蓓，等.2016-2018年某医院肺炎克雷伯菌的临床分布及耐药性分析[J].微生物学免疫学进展，2019，27（4）：54-59.
[8]	Zhang H，Yang Q，Liao K.Update of incidence and antimicrobial susceptibility trends ofEscherichia coliandKlebsiellapneumoniae isolates from Chinese intra-abdominal infection patients[J].BMC Infect Dis，2017，17（1）：776-776.
[9]	向蓉，欧焕娇，徐宁，等.肺炎克雷伯菌耐药性与抗菌药物使用情况相关性研究[J].中国医药导报，2019，29（20）159-163.
[10]	Shankar C，Veeraraghavan B，Nabarro LEB，et al.Whole genome analysis of hypervirulentKlebsiellapneumoniae isolates from community and hospital acquired bloodstream infection[J].BMC Microbiol，2018，18（1）：6.
[11]	杨宏斌，张妍.甘肃省天水地区产超广谱β-内酰胺酶大肠埃希菌致尿路感染的基因分型及耐药性分析[J].现代检验医学杂志，2019，32（3）：55-58.
[12]	赵婷，陆运涛，朱迎钢.长期住院高龄患者医院获得性肺炎病原学特点及早期炎症指标评估其预后的价值探讨[J].内科理论与实践，2019，17（4）：225-229.
[13]	李荷楠，曾吉，金炎，等.2016年中国12 家教学医院院内感染常见病原菌的分布和抗菌药物耐药监测研究[J].中华检验医学杂志，2018，41（9）：651-657.
[14]	李燕，余志红，杨燕冰.脑卒中患者尿管相关性感染的病原菌分布及耐药性分析[J].川北医学院学报，2018，33（3）：377-381.
[15]	Johnson JK，Robinson GL，Pineles LL，et al.Carbapenem MICs inEscherichia coliandKlebsiellaSpecies Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009[J].Antimicrob Agents Chemother，2017，61（4）：e01718-16.